Prelude Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Prelude Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,100	Closed	-$202K	–	2112
2021 Q2	$202K	Hold	10,100	–	–	0.01%	1378
2021 Q1	$233K	Buy	+10,100	New	+$282K	0.01%	1262
2020 Q4	–	Sell	-100	Closed	-$4K	–	2152
2020 Q3	$4K	Sell	100 -200	-67%	-$9.19K	﹤0.01%	1601
2020 Q2	$14K	Buy	+300	New	+$23.2K	﹤0.01%	1496
2019 Q2	–	Sell	-500	Closed	-$56K	–	2248
2019 Q1	$56K	Buy	+500	New	+$54.6K	﹤0.01%	1092
2015 Q1	–	Sell	-500	Closed	-$78K	–	2256
2014 Q4	$78K	Buy	+500	New	+$92.4K	0.01%	1105

Prelude Capital Management's ICPT Position: Q4 2023 in Review

Prelude Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 62,847 shares — an estimated $1.17M sold.

Prelude Capital Management first reported a position in ICPT in Q1 2017 and held it in 11 quarters. The position peaked at $2.13M in Q2 2017. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

Prelude Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Prelude Capital Management sold 62,847 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $1.17M.
Prelude Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2017 and held it in 11 quarters.
Prelude Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $2.13M in Q2 2017.
0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.